Literature DB >> 2936832

The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat.

M J Ingerman, P G Pitsakis, A F Rosenberg, M E Levison.   

Abstract

The efficacy of ciprofloxacin, BMY-28142, and ceftazidime was compared in vitro and in experimental left-sided endocarditis due to Pseudomonas aeruginosa in the rat. The dose, dosing interval, and duration of therapy were varied, and the resulting antibiotic levels in serum and vegetations were correlated with bacterial clearance from vegetations. These studies demonstrated that beta-lactams such as BMY exhibited a slow rate of bactericidal action and had no postantibiotic effect against P. aeruginosa in vitro or in vivo. As a consequence, BMY had to be given in multiple doses at relatively short intervals during which concentrations of antibiotics in vegetations were continuously in excess of the MBC for the pathogen. The earlier onset of rapid bactericidal action and the prolonged postantibiotic effect of ciprofloxacin (demonstrated in vivo and in vitro) were, in all likelihood, the factors that allowed the successful use of fewer doses of this antimicrobial agent at relatively longer dosing intervals.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936832     DOI: 10.1093/infdis/153.4.707

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Increasing Antimicrobial Resistance: Therapeutic Implications for Enterococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

Review 2.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

3.  Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model.

Authors:  S Corvaisier; P H Maire; M Y Bouvier d'Yvoire; X Barbaut; N Bleyzac; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

4.  Postantibiotic effect of penicillin plus gentamicin versus Enterococcus faecalis in vitro and in vivo.

Authors:  M T Hessen; P G Pitsakis; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

5.  Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo.

Authors:  J Renneberg; M Walder
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 7.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

Review 8.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

9.  Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.

Authors:  B Fantin; J Leggett; S Ebert; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.